Genus and Grifols have been in the spotlight recently. Alex Darwall of Devon highlighted the potential of gene editing tech for Genus, while criticizing Grifols' corporate governance. Grifols faced a significant drop in share price after Gotham City questioned ethics in a short report, hitting a 12-year low. However, the situation improved as an auditor gave an 'unqualified opinion' on Grifols' 2023 results, leading to a surge in share price by 16% following the positive report from KPMG.
Grifols shares rebound after KPMG greenlights accounts in wake of short-seller’s report https://t.co/TIKWg9A8zJ
Grifols' shares rise 16% after auditor's 2023 results opinion https://t.co/QPwIkmB4v2 https://t.co/X1nrTDmBH2
Grifols shares surge after an auditor signed off on the annual accounts of the Spanish maker of blood products https://t.co/Xz88bjvKwa
Spain's Grifols publishes 2023 results with auditor's 'unqualified opinion' https://t.co/orjKBWW3Vj https://t.co/8FiFQys7fQ
Grifols shares drop to 12-year low after new Gotham City Research report https://t.co/5G7lSdr07x https://t.co/XBEFgNXcfa
$GRFS (-12.2% pre) Grifols falls after Gotham City questions ethics in new short report https://t.co/5ppHLqWPZZ
Alex Darwall (Devon) on Genus $GNS and Grifols $GRF Genus: "New gene editing tech ... is transformational ... an eventuality ... not remotely reflected in share price" Grifols: "Corporate governance has been poor ... We see a pathway to improvement with a new outside CEO" https://t.co/FjLS2mAU5t